Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobeNewsWire • 07/20/26
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with HarrowBusiness Wire • 07/01/26
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the USZacks Investment Research • 06/11/26
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareGlobeNewsWire • 06/10/26
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law ViolationsGlobeNewsWire • 05/13/26
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/04/26
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026GlobeNewsWire • 04/27/26
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030GlobeNewsWire • 03/24/26
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?The Motley Fool • 03/24/26
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support GrowthGlobeNewsWire • 03/24/26
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual MeetingGlobeNewsWire • 03/18/26